← FDA DRUG APPROVALS

FDA ANDA · ANDA204071

SODIUM POLYSTYRENE SULFONATE

Sponsor: NUVO PHARMS INC

APPLICATION
ANDA204071
TYPE
ANDA
ORIGINAL APPROVAL
2014-11-28
LATEST ACTION
2020-02-21
ROUTE
ORAL, RECTAL, ORAL, RECTAL
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

SODIUM POLYSTYRENE SULFONATEPrescription
SODIUM POLYSTYRENE SULFONATE 15GM/BOT · POWDER · ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATEPrescription
SODIUM POLYSTYRENE SULFONATE 454GM/BOT · POWDER · ORAL, RECTAL

Approval history

2020-02-21Labeling · Supplement 3 · standardAP
2014-11-28UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →